LT3004155T - Peptidų junginys - Google Patents
Peptidų junginysInfo
- Publication number
- LT3004155T LT3004155T LTEPPCT/JP2014/002772T LT14729976T LT3004155T LT 3004155 T LT3004155 T LT 3004155T LT 14729976 T LT14729976 T LT 14729976T LT 3004155 T LT3004155 T LT 3004155T
- Authority
- LT
- Lithuania
- Prior art keywords
- peptide compound
- peptide
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013111893 | 2013-05-28 | ||
| PCT/JP2014/002772 WO2014192284A1 (en) | 2013-05-28 | 2014-05-27 | Peptide compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3004155T true LT3004155T (lt) | 2021-12-27 |
Family
ID=50942304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/JP2014/002772T LT3004155T (lt) | 2013-05-28 | 2014-05-27 | Peptidų junginys |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10087229B2 (lt) |
| EP (1) | EP3004155B1 (lt) |
| JP (2) | JP6429799B2 (lt) |
| KR (1) | KR102229051B1 (lt) |
| CN (1) | CN105209485B (lt) |
| AP (1) | AP2015008781A0 (lt) |
| AR (1) | AR096440A1 (lt) |
| AU (1) | AU2014272500B2 (lt) |
| CA (1) | CA2908581C (lt) |
| CL (1) | CL2015003031A1 (lt) |
| CY (1) | CY1124790T1 (lt) |
| DK (1) | DK3004155T3 (lt) |
| DO (1) | DOP2015000261A (lt) |
| EA (2) | EA035813B1 (lt) |
| EC (1) | ECSP15044389A (lt) |
| ES (1) | ES2900744T3 (lt) |
| GE (1) | GEP201706762B (lt) |
| HR (1) | HRP20212014T1 (lt) |
| HU (1) | HUE057361T2 (lt) |
| IL (1) | IL242005B (lt) |
| LT (1) | LT3004155T (lt) |
| MA (1) | MA38472B1 (lt) |
| MX (2) | MX373436B (lt) |
| MY (1) | MY172744A (lt) |
| PE (1) | PE20151770A1 (lt) |
| PH (1) | PH12015502391B1 (lt) |
| PL (1) | PL3004155T3 (lt) |
| PT (1) | PT3004155T (lt) |
| SG (1) | SG11201507934PA (lt) |
| SI (1) | SI3004155T1 (lt) |
| TN (1) | TN2015000451A1 (lt) |
| TW (1) | TWI638831B (lt) |
| UA (1) | UA118558C2 (lt) |
| UY (1) | UY35589A (lt) |
| WO (1) | WO2014192284A1 (lt) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3004155T (lt) | 2013-05-28 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Peptidų junginys |
| JO3575B1 (ar) * | 2015-01-09 | 2020-07-05 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| CN104846061A (zh) * | 2015-05-07 | 2015-08-19 | 中国药科大学 | 一种glp-1受体激动剂的受体亲和力测定方法 |
| CN105388239B (zh) * | 2015-12-18 | 2018-01-05 | 兆科药业（合肥）有限公司 | 一种多肽固相合成的监测方法 |
| WO2017204219A1 (ja) * | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
| US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| JOP20190211A1 (ar) * | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| WO2019140030A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| JP2021512051A (ja) | 2018-01-23 | 2021-05-13 | ギラ セラピューティクス インコーポレイテッドＧｉｌａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドｙｙ薬学的調剤物、組成物、および方法 |
| KR102379958B1 (ko) * | 2018-05-04 | 2022-04-01 | 노보 노르디스크 에이/에스 | Gip 유도체 및 이의 용도 |
| EP3826662B9 (en) * | 2018-07-23 | 2025-02-19 | Eli Lilly and Company | Method of using a gip/glp1 co-agonist for diabetes |
| CN110818771B (zh) * | 2018-08-14 | 2023-01-17 | 陈铭 | 使用氨基酸离子液体的羰基硫介导多肽合成 |
| EP3856339A1 (en) * | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| JP2022503793A (ja) * | 2018-09-24 | 2022-01-12 | 武田薬品工業株式会社 | Ｇｉｐ受容体アゴニストペプチド化合物及びその使用 |
| MX2022002115A (es) * | 2019-08-19 | 2022-03-17 | Lilly Co Eli | Metodos para preparar analogos de incretina. |
| WO2021066600A1 (ko) | 2019-10-04 | 2021-04-08 | 한미약품 주식회사 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| AR121650A1 (es) * | 2020-03-25 | 2022-06-22 | Takeda Pharmaceuticals Co | Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos |
| JP7736315B2 (ja) * | 2020-03-31 | 2025-09-09 | アンタロス メディカル アクティエボラーグ | イメージング及び治療目的のキレート部分を含む選択的ｇｉｐ受容体アゴニスト |
| BR112023000229A2 (pt) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
| MX2023000303A (es) | 2020-07-22 | 2023-02-09 | Novo Nordisk As | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| WO2022253202A1 (zh) | 2021-06-01 | 2022-12-08 | 南京知和医药科技有限公司 | 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途 |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| UY40349A (es) | 2022-07-13 | 2024-01-31 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Agonista dual de glp-1/gip, método de preparación y uso del mismo |
| CA3262093A1 (en) * | 2022-07-20 | 2024-01-25 | Viking Therapeutics, Inc. | Pharmaceutical Formulations and Methods for the Treatment of Metabolic and Liver Disorders |
| JP2025531200A (ja) | 2022-09-15 | 2025-09-19 | イーライ リリー アンド カンパニー | Ｇｉｐ及びｇｌｐ－１二重アゴニスト化合物 |
| JP2026502943A (ja) | 2022-12-30 | 2026-01-27 | アルギファルマ エーエス | 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4714434A1 (en) | 2023-05-19 | 2026-03-25 | Aulbio Co., Ltd. | Microsphere comprising thyrazepatide, method for preparing same, and pharmaceutical composition comprising same |
| EP4724471A1 (en) | 2023-06-09 | 2026-04-15 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists |
| AU2024306538A1 (en) | 2023-06-30 | 2025-12-04 | Zealand Pharma A/S | Combination therapy |
| AR134436A1 (es) * | 2023-11-22 | 2026-01-14 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario |
| JP7755031B2 (ja) | 2023-11-30 | 2025-10-15 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬 |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| TW202542174A (zh) * | 2023-12-29 | 2025-11-01 | 大陸商杭州中美華東製藥有限公司 | Glp-1/gip雙激動劑的固相合成方法 |
| TW202535912A (zh) * | 2024-01-12 | 2025-09-16 | 大陸商杭州中美華東製藥有限公司 | 長效glp-1/gip雙激動劑的鼻腔遞送藥物組合物 |
| TW202535911A (zh) * | 2024-01-12 | 2025-09-16 | 大陸商杭州中美華東製藥有限公司 | 長效glp-1/gip雙激動劑的藥物組合物 |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| JP2001504105A (ja) | 1996-11-12 | 2001-03-27 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ―１ペプチドの利用 |
| AU3087599A (en) | 1998-03-19 | 1999-10-11 | Bionebraska, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
| AU5027299A (en) | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
| JP2002538081A (ja) | 1998-12-07 | 2002-11-12 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Ｇｌｐ−１の類似体 |
| WO2001087341A1 (en) | 2000-05-16 | 2001-11-22 | Sanwa Kagaku Kenkyusho Co.,Ltd. | Agents for preventing or ameliorating insulin resistance and/or obesity |
| EP1525219B1 (en) | 2002-07-04 | 2009-05-27 | Zealand Pharma A/S | Glp-1 and methods for treating diabetes |
| EP1711523B1 (en) | 2003-12-16 | 2012-10-10 | Ipsen Pharma | Analogues of glp-1 |
| WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
| BRPI0606992A2 (pt) | 2005-02-11 | 2009-07-28 | Amylin Pharmaceuticals Inc | análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis |
| WO2006136374A2 (en) | 2005-06-20 | 2006-12-28 | Develogen Aktiengesellschaft | Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells |
| EP2051725A4 (en) | 2006-07-11 | 2011-06-15 | Harkness Pharmaceuticals Inc | METHOD FOR THE TREATMENT OF GRAIN WITH SATURATION FACTORS |
| AU2007284365A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| TWI430806B (zh) | 2006-09-13 | 2014-03-21 | Smithkline Beecham Corp | 用於投與長效降血糖藥劑之方法 |
| EP1972349A1 (en) | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | GLP-1 fusion peptides conjugated to polymer(s), their production and use |
| US8710002B2 (en) | 2007-11-23 | 2014-04-29 | Michael Rothkopf | Methods of enhancing diabetes resolution |
| DK2300035T3 (en) | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Mixed GIP-based agonists for the treatment of metabolic diseases and obesity |
| AU2009280021B2 (en) | 2008-08-07 | 2012-10-04 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
| US8748377B2 (en) | 2008-12-10 | 2014-06-10 | Glaxosmithkline Llc | Pharmaceutical compositions |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| US9260500B2 (en) | 2009-07-02 | 2016-02-16 | Takeda Pharmaceutical Company Limited | Peptide and use thereof |
| EP2528618A4 (en) * | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| SG191252A1 (en) | 2010-12-22 | 2013-07-31 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| EP2694095B1 (en) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
| WO2012168431A2 (en) | 2011-06-10 | 2012-12-13 | Novo Nordisk A/S | Polypeptides |
| WO2012167744A1 (en) * | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| US20130090285A1 (en) | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
| EP2753642B8 (en) | 2011-09-06 | 2017-12-13 | Novo Nordisk A/S | Glp-1 derivatives |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| JP6228187B2 (ja) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| JP6250034B2 (ja) | 2012-05-08 | 2017-12-20 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| US20150182461A1 (en) | 2012-06-19 | 2015-07-02 | Massachussets Institute Of Technology | Mass Production and Size Control of Nanoparticles Through Controlled Microvortices |
| CA2877358A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| HRP20180936T1 (hr) | 2012-06-21 | 2018-12-14 | Indiana University Research And Technology Corporation | Analozi glukagona koji pokazuju aktivnost prema receptoru za gip |
| JP2016503046A (ja) | 2012-12-19 | 2016-02-01 | ノヴォ ノルディスク アー／エス | コレステロール流出活性を有する新規ｇｌｐ−１受容体アゴニスト |
| HK1211232A1 (en) | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| AU2014230472A1 (en) | 2013-03-14 | 2015-10-01 | Medimmune Limited | Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity |
| LT3004155T (lt) | 2013-05-28 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Peptidų junginys |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
-
2014
- 2014-05-27 LT LTEPPCT/JP2014/002772T patent/LT3004155T/lt unknown
- 2014-05-27 CA CA2908581A patent/CA2908581C/en active Active
- 2014-05-27 KR KR1020157032121A patent/KR102229051B1/ko active Active
- 2014-05-27 HU HUE14729976A patent/HUE057361T2/hu unknown
- 2014-05-27 EP EP14729976.2A patent/EP3004155B1/en active Active
- 2014-05-27 EA EA201591891A patent/EA035813B1/ru unknown
- 2014-05-27 TW TW103118374A patent/TWI638831B/zh active
- 2014-05-27 SI SI201431933T patent/SI3004155T1/sl unknown
- 2014-05-27 PT PT147299762T patent/PT3004155T/pt unknown
- 2014-05-27 HR HRP20212014TT patent/HRP20212014T1/hr unknown
- 2014-05-27 MX MX2015015464A patent/MX373436B/es active IP Right Grant
- 2014-05-27 EA EA202090593A patent/EA202090593A3/ru unknown
- 2014-05-27 CN CN201480026613.0A patent/CN105209485B/zh active Active
- 2014-05-27 MY MYPI2015703438A patent/MY172744A/en unknown
- 2014-05-27 PE PE2015002124A patent/PE20151770A1/es unknown
- 2014-05-27 ES ES14729976T patent/ES2900744T3/es active Active
- 2014-05-27 US US14/780,579 patent/US10087229B2/en active Active
- 2014-05-27 TN TN2015000451A patent/TN2015000451A1/en unknown
- 2014-05-27 MA MA38472A patent/MA38472B1/fr unknown
- 2014-05-27 UY UY0001035589A patent/UY35589A/es not_active Application Discontinuation
- 2014-05-27 PL PL14729976T patent/PL3004155T3/pl unknown
- 2014-05-27 GE GEAP201413984A patent/GEP201706762B/en unknown
- 2014-05-27 SG SG11201507934PA patent/SG11201507934PA/en unknown
- 2014-05-27 JP JP2015555470A patent/JP6429799B2/ja active Active
- 2014-05-27 AR ARP140102090A patent/AR096440A1/es active IP Right Grant
- 2014-05-27 US US14/287,514 patent/US9200051B2/en active Active
- 2014-05-27 MX MX2019010531A patent/MX388826B/es unknown
- 2014-05-27 WO PCT/JP2014/002772 patent/WO2014192284A1/en not_active Ceased
- 2014-05-27 AU AU2014272500A patent/AU2014272500B2/en active Active
- 2014-05-27 AP AP2015008781A patent/AP2015008781A0/xx unknown
- 2014-05-27 DK DK14729976.2T patent/DK3004155T3/da active
- 2014-05-27 UA UAA201510946A patent/UA118558C2/uk unknown
-
2015
- 2015-10-11 IL IL242005A patent/IL242005B/en active IP Right Grant
- 2015-10-13 CL CL2015003031A patent/CL2015003031A1/es unknown
- 2015-10-14 PH PH12015502391A patent/PH12015502391B1/en unknown
- 2015-10-15 DO DO2015000261A patent/DOP2015000261A/es unknown
- 2015-10-21 EC ECIEPI201544389A patent/ECSP15044389A/es unknown
-
2018
- 2018-06-12 JP JP2018111494A patent/JP6570705B2/ja active Active
-
2021
- 2021-12-15 CY CY20211101100T patent/CY1124790T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301171I1 (nl) | Tigolaner | |
| NO2021038I1 (no) | lumasiran | |
| CL2015003031A1 (es) | Compuesto peptídico | |
| LT3060041T (lt) | Prostaciklino junginiai | |
| UY4298S (es) | Carcasa | |
| DK2970336T3 (da) | Tetrahydropyrrolothiazinforbindelser | |
| EP2989885A4 (en) | HARVESTER | |
| HUE037097T2 (hu) | Hõszigetelõpanel | |
| PL2994154T3 (pl) | Peptyd antydrobnoustrojowy | |
| DK2946640T3 (da) | Langmuir-probe | |
| LT3030259T (lt) | Peptidai | |
| DE102013106534B8 (de) | Chromatographiepipettenspitze | |
| NL301170I1 (nl) | Somatrogon | |
| IL240904A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| HRP20180618T1 (hr) | Spojevi fluorfenilpirazola | |
| DK2947066T3 (da) | Phenoxyalkylaminforbindelse | |
| DK3004134T3 (da) | Peptid-ligering | |
| DE112014001252A5 (de) | Aufbissschiene | |
| DK2983690T3 (da) | Neuropeptid Y-afledte peptider | |
| FI10343U1 (fi) | Mittateippi | |
| HRP20180722T1 (hr) | Spoj benzotiofena | |
| TH1501000971A (th) | สารประกอบพิแรโซโลพิริมิดีน | |
| TH1401007838A (th) | สารประกอบฟีนอกซิเอธิลไพเพอริดีน | |
| TH1401007117A (th) | สารประกอบเตตระไฮโดรไพราโซโลไพริมิดีน | |
| FI20165160A7 (fi) | Suhteellisen paikan näyttäminen |